source
- Swiss biotech Windward Bio raises $175 million in IPO to fund lung-drug development and test Tezspire competitorWindward Bio, a Swiss immune‑drug developer, completed a $175 million initial public offering, selling about 10.3 million shares at $17 each. The company began trading on the exchange under the tic…
- bioQuad recalls OsteoDenx capsules after discovering undeclared milk, warning allergic consumersbioQuad Life Sciences announced a recall of two lots of its OsteoDenx dietary supplement capsules because they contain undeclared milk. The presence of milk, specifically lactoferrin derived from…